Need a report that reflects how COVID-19 has impacted this market and its growth?
The North America Blood Glucose Monitoring Market is expected to register a CAGR greater than 8% over the forecast period, 2022-2027.
In North America diabetes incidence for type 2 diabetes as well as other diabetes, forms were numerically higher in individuals with Covid-19. Insulin resistance and impaired insulin secretion have been described in individuals without diabetes history who recovered from SARS-CoV-2 infections. It has been suggested that diagnosis and treatment of post-Covid syndrome require integrated rather than disease-specific approaches.
There has been a tremendous increase in the diabetic population worldwide, over the past decade. Several reports and surveys documented a drastic increase in the diabetic population, based on the changes in lifestyles and habits. The growing diabetic population acts as a driver for Blood monitoring devices, such as CGM. In developed countries, close to 90% of Type-1 diabetic patients use a glucometer. During the forecast period, close to 50% of Type-2 patients are expected to use a glucometer.
North America dominates the global insulin therapeutics market, owing to the high prevalence of diabetes in the region because of the sedentary lifestyle and the launch of new drugs in the region. The United States is expected to grow tremendously during the forecast period, owing to factors, such as the high prevalence of obesity and increasing awareness regarding diabetes care in the region
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Scope of the Report
The North America Blood Glucose Monitoring Market is expected to register a CAGR greater than 8% over the forecast period. The North America Blood Glucose Monitoring Market is segmented by Type (Self-monitoring Blood Glucose, and Continuous Glucose Monitoring), Component (Glucometer Devices, Test Strips, Lancets, Sensors, and Durables), and Geography. The report offers market size and forecasts for all the above segments in value (USD billion), and volume.
Key Market Trends
Continuous Glucose Monitoring Holds Highest Market Share in Europe Blood Glucose Monitoring Market.
CGMs are used to deliver a further descriptive picture of blood glucose patterns and trends than what can be achieved by traditional routine checking of glucose levels at set intervals. The current CGM devices can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays. Most of the real-time CGMs can offer an alert to patients, parents, or caregivers during actual or pending glycemic visits, to facilitate timely management of blood glucose. This factor, along with the fact that CGM devices are becoming cheaper with the advent of new technologies, like cell phone integration, the CGM market is expected to witness steady growth during the forecast period.
The use of CGM by Type-1 diabetic patients is very less, as compared to Type-2 diabetic patients. But the expenditure incurred by Type-1 diabetic patients on these devices is nearly double that of Type-2 diabetics. The newest CGM models, the Abbott Freestyle Libre and the Dexcom G6 overcame many technical barriers. However, high costs and uncertainties about their efficacy and necessity have kept CGM from being widely used by people with Type-2 diabetes. Moreover, to lower the cost burden of diabetic patients in the United States, Abbott introduced a new, lower-priced category with Libre, at around USD 75 to USD 150 each month (2 sensors that last 14 days each).
The rise in national awareness of diabetes is anticipated to drive the adoption of both SMBGs and CGMs on account of the prognostic and diagnostic treatment of diabetes.
To understand key trends, Download Sample Report
The United States is Expected to Dominate the North America Blood Glucose Monitoring Market.
In the United States, the prevalence of diabetes has increased dramatically during the last two decades, a fact driven by the increased prevalence of obesity and lifestyle changes. Diabetes ranks among the fast-growing chronic diseases in the United States. About 1.75 million US citizens are diagnosed with diabetes every year. The country also has the highest obese population, which is a prominent cause of Type 2 diabetes.
In the United States, there are several innovations by startups, like Glooko, OneDrop, Verily, Vacate, Insulet, Noom, Bigfoot Biomedical, Virta Health, and Diabeloop, Orgenesis launched in the market.
The market for diabetes care devices is expected to experience steady growth in the coming years, due to the greater prevalence of obesity, owing to less physical activity, unhealthy food habits, and other lifestyle factors. Abbott and Dexcom received FDA approval to use continuous glucose monitoring in US hospitals, for coronavirus-affected people. Dexcom began shipping CGMs to hospitals in April 2020. It plans to make 100,000 sensors for hospitals, at low costs. The company has been planning to donate 10,000 phones and CGM readers to hospitals, for scanning those sensors.
The growing awareness among people, regarding advanced diabetes care products, may positively impact the North American diabetes care devices market in the coming years.
To understand geography trends, Download Sample Report
The blood glucose monitoring market is highly fragmented, with few major manufacturers present in the market. The CGM devices market is dominated by a few major players, like Dexcom, Medtronics, Abbott, and Senseonics. The market for BGM devices comprises more generic players like Roche, LifeScan, Arkray, Ascensia, etc. Technological innovations in the recent past helped the companies to strengthen their market presence.
- In March 2022, Dexcom released G7 first in the United Kingdom and will expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.
- In Feb 2021, Roche announced the launch of the new Accu-Chek Instant system, a new "connected" blood glucose monitoring (BGM) system, which supports and enables Roche’s approach of integrated Personalised Diabetes Management (iPDM). Accu-Chek Instant features Bluetooth-enabled connectivity to the mySugr app, allowing wireless transfer of blood glucose results to the mySugr app.
Table of Contents
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1.1 Self-monitoring Blood Glucose Devices
18.104.22.168 By Component (Value and Volume, 2016 - 2027)
22.214.171.124.1 Glucometer Devices
126.96.36.199.2 Test Strips
5.1.2 Continuous Glucose Monitoring
188.8.131.52 By Component (Value and Volume, 2016 - 2027)
5.2.1 United States (Value and Volume, 2016 - 2027)
184.108.40.206 Self-monitoring Blood Glucose
220.127.116.11.1 By Component (Glucometer Device, Test strips, Lancets)
18.104.22.168 Continuous Glucose Monitoring
22.214.171.124.1 By Component (Sensors and Durables)
5.2.2 Canada (Value and Volume, 2016 - 2027)
126.96.36.199 Self-monitoring Blood Glucose
188.8.131.52.1 By Component (Glucometer Device, Test strips, Lancets)
184.108.40.206 Continuous Glucose Monitoring
220.127.116.11.1 By Component (Sensors and Durables)
5.2.3 Rest of North America (Value and Volume, 2016 - 2027)
18.104.22.168 Self-monitoring Blood Glucose
22.214.171.124.1 By Component (Glucometer Device, Test strips, Lancets)
126.96.36.199 Continuous Glucose Monitoring
188.8.131.52.1 By Component (Sensors and Durables)
6. MARKET INDICATORS
6.1 Type-1 Diabetes Population (2016 - 2027)
6.2 Type-2 Diabetes Population (2016 - 2027)
7. COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Abbott Diabetes Care
7.1.2 F. Hoffmann-La Roche AG
7.1.3 Johnson & Johnson
7.1.7 Ascensia Diabetes Care
7.1.8 Agamatrix Inc.
7.1.9 Bionime Corporation
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The North America Blood Glucose Monitoring Market market is studied from 2016 - 2027.
What is the growth rate of North America Blood Glucose Monitoring Market?
The North America Blood Glucose Monitoring Market is growing at a CAGR of >8% over the next 5 years.
What is North America Blood Glucose Monitoring Market size in 2016?
The North America Blood Glucose Monitoring Market is valued at 11 Billion USD in 2016.
What is North America Blood Glucose Monitoring Market size in 2027?
The North America Blood Glucose Monitoring Market is valued at 17 Billion USD in 2027.
Who are the key players in North America Blood Glucose Monitoring Market?
Dexcom, Johnson & Johnson, Medtronics, F. Hoffmann-La Roche AG, Abbott Diabetes Care are the major companies operating in North America Blood Glucose Monitoring Market.